Find News

Filter articles

Showing 3161 to 3170 of 3417 results

Generics file Teva response in Copaxone battle


A group of generic drug manufacturers has asked the US Supreme Court to allow a ruling that grants them permission to market a version of Teva’s multiple sclerosis drug Copaxone (glatiramer acetate).

UK High Court strikes down Herceptin patents

UK14-04-2014Legal developments

The UK High Court has invalidated two patents covering Roche’s breast cancer drug Herceptin (trastuzumab) after a challenge by generic drug maker Hospira.

Mintz Levin adds three in Boston


Law firm Mintz Levin Cohn Ferris Glovsky and Popeo PC has added three partners to its IP team.

IP group joins O'Melveny’s New York office


US law firm O’Melveny & Myers LLP has hired Lisa Barons Pensabene, Marc Pensabene, and Filko Prugo at its New York office.

Mallinckrodt picks up Acthar in Questcor merger

Ireland09-04-2014Mergers & acquisitions

Dublin-based Mallinckrodt Pharmaceuticals has announced it will buy US biopharmaceutical company Questcor Pharmaceuticals for $5.6 billion.

Purdue sues Teva to block OxyContin challenge


OxyContin (oxycodone hydrochloride) maker Purdue Pharma has filed suit against Teva to stop the generic drug maker trying to litigate claims to a patent for which it had filed a Paragraph III certification.

Teva asks US Supreme Court to stay ruling in Copaxone case

US08-04-2014Legal developments

Teva has filed an application with the US Supreme Court to stay a ruling by the US Court of Appeals for the Federal Circuit that allowed generic drug makers to enter the market before the expiry of Teva’s patents covering its $4.3 billion-a-year multiple sclerosis drug Copaxone.

Sun Pharma to acquire rival Ranbaxy for $3.2bn

India07-04-2014Mergers & acquisitions

Mumbai-based Sun Pharmaceutical Industries is buying Indian rival Ranbaxy Laboratories in a merger worth $3.2 billion, the companies have confirmed.

Eli Lilly drafts in Prasco to market Evista generic


Generic drug maker Prasco Laboratories has agreed to market and distribute an authorised generic version of Eli Lilly’s Evista (raloxifene hydrochloride) in the US.

Cooley expands life sciences patent team


Cooley LLP has recruited Ivor Elrifi and Heidi Erlacher to the patent counselling team serving the life sciences and technology sectors.

Showing 3161 to 3170 of 3417 results